SlideShare ist ein Scribd-Unternehmen logo

Clinical Trial Requirements: Key US vs. EU Similarities and Differences

•Als PPT, PDF herunterladen•
•
S
shivampharma88
1 von 33
Clinical Trial Requirements Similarities and Differences US vs. EU Anita Fenty Covance, Inc
OBJECTIVES ,[object Object]
LEGAL FRAMEWORK ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLINICAL TRIAL APPLICATION US ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CLINICAL TRIAL APPLICATION EU ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
INSTITUTIONAL REVIEW BOARD/ ETHICS COMMITTEE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
CONDUCT OF CLINICAL TRIAL US ,[object Object],[object Object],[object Object],[object Object]
CONDUCT OF CLINICAL TRIAL EU ,[object Object],[object Object],[object Object]
ESSENTIAL DOCUMENT RECORD RETENTION US ,[object Object],[object Object]
ESSENTIAL DOCUMENT RECORD RETENTION US ,[object Object],[object Object]
ESSENTIAL DOCUMENT RECORD RETENTION EU ,[object Object],[object Object],[object Object]
ESSENTIAL DOCUMENT RECORD RETENTION EU ,[object Object],[object Object],[object Object],[object Object]
INVESTIGATIONAL MEDICINAL PRODUCT (IMP) REQUIREMENTS US ,[object Object],[object Object]
INVESTIGATIONAL MEDICINAL PRODUCT (IMP) REQUIREMENTS EU ,[object Object],[object Object],[object Object]
INVESTIGATIONAL MEDICINAL PRODUCT (IMP) REQUIREMENTS EU ,[object Object],[object Object]
ADVERSE EVENT REPORTING US ,[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING US ,[object Object],[object Object],[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING US ,[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING US ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING EU ,[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING EU ,[object Object],[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING EU ,[object Object],[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING EU ,[object Object],[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING EU ,[object Object],[object Object]
ADVERSE EVENT REPORTING EU ,[object Object],[object Object],[object Object],[object Object],[object Object]
ADVERSE EVENT REPORTING EU ,[object Object],[object Object],[object Object],[object Object],[object Object]
REGULATORY COMPLIANCE US ,[object Object],[object Object]
REGULATORY COMPLIANCE US ,[object Object],[object Object],[object Object]
REGULATORY COMPLIANCE US ,[object Object],[object Object],[object Object]
REGULATORY COMPLIANCE US ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
REGULATORY COMPLIANCE EU ,[object Object],[object Object],[object Object],[object Object],[object Object]
REGULATORY COMPLIANCE EU ,[object Object],[object Object],[object Object],[object Object],[object Object]
DISCUSSION/ QUESTIONS/COMMENTS ,[object Object],[object Object],[object Object]

Empfohlen

ANDA
ANDAANDA
ANDASagar Savale
 
Emea guidelines
Emea guidelinesEmea guidelines
Emea guidelinesClapbio
 
Post approval of drugs
Post approval of drugsPost approval of drugs
Post approval of drugsSunil Boreddy Rx
 
Anda
AndaAnda
AndaMalla Reddy College of Pharmacy
 
ICH - quality guidelines
ICH - quality guidelinesICH - quality guidelines
ICH - quality guidelinesManishShankarpure
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in euRajaniKarpur
 
Drug approval in US, EU & India
Drug approval in US, EU & IndiaDrug approval in US, EU & India
Drug approval in US, EU & IndiaSweta Yadav
 
Hatch waxman act & amendments ppt
Hatch waxman act & amendments pptHatch waxman act & amendments ppt
Hatch waxman act & amendments pptAlexa Jacob
 

Empfohlen

ANDA
ANDAANDA
ANDASagar Savale
 
Emea guidelines
Emea guidelinesEmea guidelines
Emea guidelinesClapbio
 
Post approval of drugs
Post approval of drugsPost approval of drugs
Post approval of drugsSunil Boreddy Rx
 
Anda
AndaAnda
AndaMalla Reddy College of Pharmacy
 
ICH - quality guidelines
ICH - quality guidelinesICH - quality guidelines
ICH - quality guidelinesManishShankarpure
 
Marketing authorization procedures in eu
Marketing authorization procedures in euMarketing authorization procedures in eu
Marketing authorization procedures in euRajaniKarpur
 
Drug approval in US, EU & India
Drug approval in US, EU & IndiaDrug approval in US, EU & India
Drug approval in US, EU & IndiaSweta Yadav
 
Hatch waxman act & amendments ppt
Hatch waxman act & amendments pptHatch waxman act & amendments ppt
Hatch waxman act & amendments pptAlexa Jacob
 
Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionDoninder Hooda
 
Abriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingAbriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingshahnawazQuadir
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGaurav Sharma
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYdatchayani
 
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdfINVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdfAmeena Kadar
 
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...BhavikaAPatel
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsNimmiRoy
 
Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (BhanuSriChandanaKnch
 
Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)Rishabh Agrawal
 
NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)GOKULAKRISHNAN S
 
Abbrevated New Drug Applications- Basics
Abbrevated New Drug Applications- BasicsAbbrevated New Drug Applications- Basics
Abbrevated New Drug Applications- BasicsAPCER Life Sciences
 
Paper nda
Paper nda Paper nda
Paper nda Pradeep Gusain
 
Emea
EmeaEmea
EmeaRanjeet Singh
 
eCTD Submissions
eCTD SubmissionseCTD Submissions
eCTD SubmissionsGautam Halder
 
NDA Application.pptx
NDA Application.pptxNDA Application.pptx
NDA Application.pptxVenugopal N
 
MHRA
MHRAMHRA
MHRAMD Jahidul Islam
 
investigational medicinal product dossier and Dossier.
investigational medicinal product dossier and Dossier.investigational medicinal product dossier and Dossier.
investigational medicinal product dossier and Dossier.Gaurav Patil
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureOffice of Health Economics
 
Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.rkreddy98666
 
drug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china ...sonali mishradrug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china ...sonali mishraSonaliMishra64
 
Bipolar disorder
Bipolar disorderBipolar disorder
Bipolar disorderheyitsmarylou
 
Tenney--LinkedIn Globalization (July 2008)
Tenney--LinkedIn Globalization (July 2008)Tenney--LinkedIn Globalization (July 2008)
Tenney--LinkedIn Globalization (July 2008)merletenney
 

Weitere ähnliche Inhalte

Was ist angesagt?

Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionDoninder Hooda
 
Abriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingAbriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingshahnawazQuadir
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGaurav Sharma
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYdatchayani
 
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdfINVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdfAmeena Kadar
 
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...BhavikaAPatel
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsNimmiRoy
 
Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (BhanuSriChandanaKnch
 
Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)Rishabh Agrawal
 
NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)GOKULAKRISHNAN S
 
Abbrevated New Drug Applications- Basics
Abbrevated New Drug Applications- BasicsAbbrevated New Drug Applications- Basics
Abbrevated New Drug Applications- BasicsAPCER Life Sciences
 
NDA Application.pptx
NDA Application.pptxNDA Application.pptx
NDA Application.pptxVenugopal N
 
investigational medicinal product dossier and Dossier.
investigational medicinal product dossier and Dossier.investigational medicinal product dossier and Dossier.
investigational medicinal product dossier and Dossier.Gaurav Patil
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureOffice of Health Economics
 
Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.rkreddy98666
 
drug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china ...sonali mishradrug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china ...sonali mishraSonaliMishra64
 

Was ist angesagt? (20)

Marketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European Union
 
Abriviated new drug application 505(j) filling
Abriviated new drug application 505(j) fillingAbriviated new drug application 505(j) filling
Abriviated new drug application 505(j) filling
 
Guidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or andaGuidance for industry changes to an approved nda or anda
Guidance for industry changes to an approved nda or anda
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
 
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdfINVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
 
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...
Changes to an approved NDA and ANDA Regulatory considerations for manufacturi...
 
Regulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologicsRegulatory guidance and guidelines for filing and approval for biologics
Regulatory guidance and guidelines for filing and approval for biologics
 
Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (Global submission of abbreviated new drug application (
Global submission of abbreviated new drug application (
 
Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)Medicines and Healthcare products Regulatory Agency(MHRA)
Medicines and Healthcare products Regulatory Agency(MHRA)
 
NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)NEW DRUG APPLICATION (NDA)
NEW DRUG APPLICATION (NDA)
 
Abbrevated New Drug Applications- Basics
Abbrevated New Drug Applications- BasicsAbbrevated New Drug Applications- Basics
Abbrevated New Drug Applications- Basics
 
Paper nda
Paper nda Paper nda
Paper nda
 
Emea
EmeaEmea
Emea
 
eCTD Submissions
eCTD SubmissionseCTD Submissions
eCTD Submissions
 
NDA Application.pptx
NDA Application.pptxNDA Application.pptx
NDA Application.pptx
 
MHRA
MHRAMHRA
MHRA
 
investigational medicinal product dossier and Dossier.
investigational medicinal product dossier and Dossier.investigational medicinal product dossier and Dossier.
investigational medicinal product dossier and Dossier.
 
Marketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised ProcedureMarketing Authorisations in the EU: The Centralised Procedure
Marketing Authorisations in the EU: The Centralised Procedure
 
Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.Challenges in regulatory filing of generic products in Europe and Malyasia.
Challenges in regulatory filing of generic products in Europe and Malyasia.
 
drug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china ...sonali mishradrug registrastion requirements in china ...sonali mishra
drug registrastion requirements in china ...sonali mishra
 

Andere mochten auch

Tenney--LinkedIn Globalization (July 2008)
Tenney--LinkedIn Globalization (July 2008)Tenney--LinkedIn Globalization (July 2008)
Tenney--LinkedIn Globalization (July 2008)merletenney
 
Investor Presentation
Investor PresentationInvestor Presentation
Investor Presentationmark_v1
 
Regulatory Trends Of Pharmaceuticals I Bric Countries
Regulatory Trends Of Pharmaceuticals I Bric CountriesRegulatory Trends Of Pharmaceuticals I Bric Countries
Regulatory Trends Of Pharmaceuticals I Bric Countriesshivampharma88
 
The dangers of daylight saving time
The dangers of daylight saving timeThe dangers of daylight saving time
The dangers of daylight saving timeEdward pzizz
 

Andere mochten auch (7)

Bipolar disorder
Bipolar disorderBipolar disorder
Bipolar disorder
 
Tenney--LinkedIn Globalization (July 2008)
Tenney--LinkedIn Globalization (July 2008)Tenney--LinkedIn Globalization (July 2008)
Tenney--LinkedIn Globalization (July 2008)
 
Investor Presentation
Investor PresentationInvestor Presentation
Investor Presentation
 
Bipolar disorder
Bipolar disorderBipolar disorder
Bipolar disorder
 
Regulatory Trends Of Pharmaceuticals I Bric Countries
Regulatory Trends Of Pharmaceuticals I Bric CountriesRegulatory Trends Of Pharmaceuticals I Bric Countries
Regulatory Trends Of Pharmaceuticals I Bric Countries
 
Writing portfolio
Writing portfolioWriting portfolio
Writing portfolio
 
The dangers of daylight saving time
The dangers of daylight saving timeThe dangers of daylight saving time
The dangers of daylight saving time
 

Ähnlich wie Clinical Trial Requirements: Key US vs. EU Similarities and Differences

Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuAngelinabarfield
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 
European Clinical Trial Safety Focus
European Clinical Trial Safety FocusEuropean Clinical Trial Safety Focus
European Clinical Trial Safety FocusVaska Toné
 
Medical device regulation US, European Union and India
Medical device regulation US, European Union and IndiaMedical device regulation US, European Union and India
Medical device regulation US, European Union and IndiaCSIR-URDIP, NCL Campus, Pune
 
Pharmacovigilance Audits: Is the USA behind the curve?
Pharmacovigilance Audits: Is the USA behind the curve?Pharmacovigilance Audits: Is the USA behind the curve?
Pharmacovigilance Audits: Is the USA behind the curve?Medpace
 
Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...Diane Hatziioanou
 
The Importance of Developing a Global Regulatory Strategy towards the Goal of...
The Importance of Developing a Global Regulatory Strategy towards the Goal of...The Importance of Developing a Global Regulatory Strategy towards the Goal of...
The Importance of Developing a Global Regulatory Strategy towards the Goal of...Life Sciences Network marcus evans
 
Investigational medicinal product dossier
Investigational medicinal product dossierInvestigational medicinal product dossier
Investigational medicinal product dossierMayuriGhavate
 
Vitafoods eu clinical trials regulation
Vitafoods eu clinical trials regulationVitafoods eu clinical trials regulation
Vitafoods eu clinical trials regulationAxon Lawyers
 
Reporting adverse events under COVID-19 to FDA
Reporting adverse events under COVID-19 to FDAReporting adverse events under COVID-19 to FDA
Reporting adverse events under COVID-19 to FDAChristine Zomorodian
 
Organization structure of EMA and EDQM active Substance Master File.pptx
Organization structure of EMA and EDQM active Substance Master File.pptxOrganization structure of EMA and EDQM active Substance Master File.pptx
Organization structure of EMA and EDQM active Substance Master File.pptxBhavikaAPatel
 
DRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxDRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxAmeena Kadar
 
presentation-ema-experience-mdr-implementation_en.pdf
presentation-ema-experience-mdr-implementation_en.pdfpresentation-ema-experience-mdr-implementation_en.pdf
presentation-ema-experience-mdr-implementation_en.pdfBalaji Kuzhandhaivelu
 
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...QPS Holdings, LLC
 
Clinical research : Drug regulatory affairs and Pharmacovigilance.
Clinical research : Drug regulatory affairs and Pharmacovigilance.Clinical research : Drug regulatory affairs and Pharmacovigilance.
Clinical research : Drug regulatory affairs and Pharmacovigilance.ProfDnyaneshwariJosh
 
Summary Of Schedule Y
Summary Of Schedule YSummary Of Schedule Y
Summary Of Schedule Ylekshmilnair
 
Investigation of medicinal product dossier (IMPD)
Investigation of medicinal product dossier (IMPD)Investigation of medicinal product dossier (IMPD)
Investigation of medicinal product dossier (IMPD)Himal Barakoti
 
investigation medical products dossier
investigation medical products dossierinvestigation medical products dossier
investigation medical products dossierKarthik Karan
 
Investigational medical product dossier
Investigational medical product dossierInvestigational medical product dossier
Investigational medical product dossierSachinFartade
 
pharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONpharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONgarimasaini33
 

Ähnlich wie Clinical Trial Requirements: Key US vs. EU Similarities and Differences (20)

Drug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And EuDrug Safety Regulations In The Us And Eu
Drug Safety Regulations In The Us And Eu
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
European Clinical Trial Safety Focus
European Clinical Trial Safety FocusEuropean Clinical Trial Safety Focus
European Clinical Trial Safety Focus
 
Medical device regulation US, European Union and India
Medical device regulation US, European Union and IndiaMedical device regulation US, European Union and India
Medical device regulation US, European Union and India
 
Pharmacovigilance Audits: Is the USA behind the curve?
Pharmacovigilance Audits: Is the USA behind the curve?Pharmacovigilance Audits: Is the USA behind the curve?
Pharmacovigilance Audits: Is the USA behind the curve?
 
Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...Key current and future regulatory challenges in the Medical Device and/or IVD...
Key current and future regulatory challenges in the Medical Device and/or IVD...
 
The Importance of Developing a Global Regulatory Strategy towards the Goal of...
The Importance of Developing a Global Regulatory Strategy towards the Goal of...The Importance of Developing a Global Regulatory Strategy towards the Goal of...
The Importance of Developing a Global Regulatory Strategy towards the Goal of...
 
Investigational medicinal product dossier
Investigational medicinal product dossierInvestigational medicinal product dossier
Investigational medicinal product dossier
 
Vitafoods eu clinical trials regulation
Vitafoods eu clinical trials regulationVitafoods eu clinical trials regulation
Vitafoods eu clinical trials regulation
 
Reporting adverse events under COVID-19 to FDA
Reporting adverse events under COVID-19 to FDAReporting adverse events under COVID-19 to FDA
Reporting adverse events under COVID-19 to FDA
 
Organization structure of EMA and EDQM active Substance Master File.pptx
Organization structure of EMA and EDQM active Substance Master File.pptxOrganization structure of EMA and EDQM active Substance Master File.pptx
Organization structure of EMA and EDQM active Substance Master File.pptx
 
DRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxDRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptx
 
presentation-ema-experience-mdr-implementation_en.pdf
presentation-ema-experience-mdr-implementation_en.pdfpresentation-ema-experience-mdr-implementation_en.pdf
presentation-ema-experience-mdr-implementation_en.pdf
 
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
Regulatory and Timeline Advantages for Early Clinical Research in The Netherl...
 
Clinical research : Drug regulatory affairs and Pharmacovigilance.
Clinical research : Drug regulatory affairs and Pharmacovigilance.Clinical research : Drug regulatory affairs and Pharmacovigilance.
Clinical research : Drug regulatory affairs and Pharmacovigilance.
 
Summary Of Schedule Y
Summary Of Schedule YSummary Of Schedule Y
Summary Of Schedule Y
 
Investigation of medicinal product dossier (IMPD)
Investigation of medicinal product dossier (IMPD)Investigation of medicinal product dossier (IMPD)
Investigation of medicinal product dossier (IMPD)
 
investigation medical products dossier
investigation medical products dossierinvestigation medical products dossier
investigation medical products dossier
 
Investigational medical product dossier
Investigational medical product dossierInvestigational medical product dossier
Investigational medical product dossier
 
pharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONpharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNION
 

Clinical Trial Requirements: Key US vs. EU Similarities and Differences

  • 1. Clinical Trial Requirements Similarities and Differences US vs. EU Anita Fenty Covance, Inc
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.